Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb
Executive Summary
US FDA pilot program linking drug approval documents to sponsors' clinical study reports will improve review efficiency and access to information by medical researchers and drug developers, commissioner says; move also could aid sponsors when it comes to reimbursement decision-making, Foley and Lardner's Rosen predicts.
You may also be interested in...
Clinical Study Report Release Could Compromise Patient Privacy, Groups Say
US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.
US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals
The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.
Postmarketing Commitments: Sponsors Often Do Not Publish Results Of New Clinical Trials
Only 15% of postmarketing commitments for drugs approved in 2009-2012 were for clinical trials and only half of these were published, study finds; authors call for US FDA to provide more trial information.